



AF/1636
IFW

PATENT
ATTORNEY DOCKET NO. 00786/351006

Certificate of Mailing: Date of Deposit: November 22, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis

Printed name of person mailing correspondence

Janet D'Annunzio-Ellis
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gary Ruvkun et al. Art Unit: 1636
Serial No.: 09/963,693 Examiner: S. Kaushal
Filed: September 25, 2001 Customer No.: 21559
Title: THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED
GLUCOSE TOLERANCE CONDITIONS

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

11/26/2004 AWONDAF1 00000057 09963693

01 FC:1806


180.00 DP

This statement is being filed after the mailing of a final Office action or a Notice of Allowance, but before payment of the issue fee. I, the undersigned, hereby certify that each item of information in this statement was cited in a search report from a corresponding international application, dated November 2, 2004, which is not more than three months prior to the filing of this statement. A check for \$180.00 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.


Respectfully submitted,

Date: 22 November 2004



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 00786/351006 Serial No. 09/963,693 Applicant Gary Ruvkun et al. Filing Date September 25, 2001 Group 1636 IDS Filed November 22, 2004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. § 1.98(b))						
U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Stern et al., "The Human GRB2 and <i>Drosophila Drk</i> Genes Can Functionally Replace the <i>Caenorhabditis elegans</i> Cell Signaling Gene <i>sem-5</i> ," <i>Mol. Biol. Cell</i> 4(11):1175-1188 (1993).					
	Levitan et al., "Assessment of Normal and Mutant Human Presenilin Function in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 93:14940-14944 (1996).					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						